ClinicalTrials.gov
History of Changes for Study: NCT02041533
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
Latest version (submitted February 2, 2023) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 January 19, 2014 None (earliest Version on record)
2 February 28, 2014 Study Status
3 March 26, 2014 Recruitment Status, Study Status and Contacts/Locations
4 April 29, 2014 Contacts/Locations, Study Status and References
5 May 7, 2014 Contacts/Locations and Study Status
6 May 27, 2014 Contacts/Locations and Study Status
7 May 30, 2014 Study Status
8 July 4, 2014 Contacts/Locations and Study Status
9 July 9, 2014 Contacts/Locations and Study Status
10 July 23, 2014 Contacts/Locations and Study Status
11 August 11, 2014 Contacts/Locations and Study Status
12 August 28, 2014 Contacts/Locations and Study Status
13 September 15, 2014 Contacts/Locations and Study Status
14 September 22, 2014 Contacts/Locations and Study Status
15 October 13, 2014 Contacts/Locations and Study Status
16 October 30, 2014 Contacts/Locations and Study Status
17 November 13, 2014 Contacts/Locations and Study Status
18 November 20, 2014 Contacts/Locations and Study Status
19 December 5, 2014 Contacts/Locations and Study Status
20 December 31, 2014 Contacts/Locations and Study Status
21 January 27, 2015 Contacts/Locations and Study Status
22 February 26, 2015 Contacts/Locations, Study Status and Sponsor/Collaborators
23 March 5, 2015 Contacts/Locations and Study Status
24 March 23, 2015 Contacts/Locations and Study Status
25 April 13, 2015 Contacts/Locations and Study Status
26 April 20, 2015 Contacts/Locations and Study Status
27 May 6, 2015 Contacts/Locations, Study Status and Study Design
28 May 20, 2015 Study Status
29 June 3, 2015 Study Status
30 June 22, 2015 Contacts/Locations and Study Status
31 July 3, 2015 Contacts/Locations and Study Status
32 July 17, 2015 Contacts/Locations and Study Status
33 August 4, 2015 Contacts/Locations and Study Status
34 August 18, 2015 Study Status
35 September 3, 2015 Contacts/Locations and Study Status
36 September 16, 2015 Contacts/Locations and Study Status
37 October 5, 2015 Recruitment Status, Contacts/Locations and Study Status
38 October 15, 2015 Study Status
39 November 4, 2015 Contacts/Locations and Study Status
40 November 18, 2015 Study Status
41 December 8, 2015 Study Status and Contacts/Locations
42 December 21, 2015 Study Status
43 January 6, 2016 Study Status
44 January 21, 2016 Study Status
45 January 26, 2016 Study Status
46 February 10, 2016 Study Status
47 February 25, 2016 Study Status
48 March 11, 2016 Study Status
49 March 28, 2016 Study Status
50 April 12, 2016 Study Status
51 April 21, 2016 Study Status
52 April 25, 2016 Study Status
53 May 10, 2016 Study Status
54 May 25, 2016 Study Status
55 June 9, 2016 Study Status
56 June 24, 2016 Study Status
57 July 11, 2016 Study Status
58 July 26, 2016 Study Status
59 August 8, 2016 Study Status
60 August 23, 2016 Study Status
61 September 15, 2016 Study Status
62 September 23, 2016 Study Status
63 October 7, 2016 Study Status
64 October 26, 2016 Study Status
65 November 8, 2016 Study Status
66 November 30, 2016 Study Status
67 December 6, 2016 Study Status
68 December 23, 2016 Study Status
69 January 5, 2017 Study Status
70 January 23, 2017 Contacts/Locations and Study Status
71 January 27, 2017 Study Status
72 February 16, 2017 Study Status
73 March 3, 2017 Study Status
74 March 29, 2017 Study Status
75 April 17, 2017 Contacts/Locations and Study Status
76 June 26, 2017 Study Status, Outcome Measures, Contacts/Locations, References, Study Design, Oversight and Results
77 July 25, 2017 Participant Flow and Study Status
78 January 18, 2018 Contacts/Locations and Study Status
79 August 21, 2019 Contacts/Locations, Study Status, References and Outcome Measures
80 November 15, 2019 Study Status and Contacts/Locations
81 December 10, 2019 Study Status
82 January 24, 2020 Study Status and Contacts/Locations
83 May 14, 2020 Study Status and Contacts/Locations
84 June 16, 2020 Study Status
85 July 6, 2020 Contacts/Locations and Study Status
86 June 9, 2021 Contacts/Locations and Study Status
87 March 8, 2022 Contacts/Locations, Study Status, References, Eligibility and Oversight
88 May 2, 2022 Study Status and Contacts/Locations
89 July 19, 2022 Recruitment Status, Study Status and Contacts/Locations
90 February 2, 2023 Adverse Events, Outcome Measures, Participant Flow, Baseline Characteristics, Contacts/Locations, Study Status, More Information and Study Design
Comparison Format:
Scroll up to access the controls
Study NCT02041533
Submitted Date:  December 5, 2014 (v19)
Open or close this module Study Identification
Unique Protocol ID: CA209-026
Brief Title: An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
Official Title: An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer
Secondary IDs: 2012-004502-93 [EudraCT Number]
Open or close this module Study Status
Record Verification: May 2014
Overall Status: Recruiting
Study Start: March 2014
Primary Completion: January 2017 [Anticipated]
Study Completion: January 2018 [Anticipated]
First Submitted: January 19, 2014
First Submitted that
Met QC Criteria:		 January 19, 2014
First Posted: January 22, 2014 [Estimate]
Last Update Submitted that
Met QC Criteria:		 December 5, 2014
Last Update Posted: December 8, 2014 [Estimate]
Open or close this module Sponsor/Collaborators
Sponsor: Bristol-Myers Squibb
Responsible Party: Sponsor
Collaborators:
Open or close this module Oversight
U.S. FDA-regulated Drug:
U.S. FDA-regulated Device:
Data Monitoring: Yes
Open or close this module Study Description
Brief Summary: The purpose of this study is to show that Nivolumab will improve progression free survival in subjects with strongly Stage IV or Recurrent PD-L1+ non-small cell lung cancer when compared to chemotherapy
Detailed Description:
Open or close this module Conditions
Conditions: Stage IV or Recurrent Non-Small Cell Lung Cancer
Keywords:
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Treatment
Study Phase: Phase 3
Interventional Study Model: Parallel Assignment
Number of Arms: 2
Masking: None (Open Label)
Allocation: Randomized
Enrollment: 495 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Experimental: Arm A: Nivolumab subjects
Nivolumab solution for Injection 3 mg/kg Intravenous every 2 weeks until disease progression, discontinuation due to unacceptable toxicity, withdrawal of consent or study closure
 Biological: Nivolumab
Other Names:
  • BMS-936558
  • MDX-1106
Active Comparator: Arm B: Investigator's Choice Chemotherapy

Investigator's Choice Chemotherapy administered in 3-week cycles up to a maximum of 6 cycles of Intravenous injection until disease progression, unacceptable toxicity or completion of the 6 cycles, whichever comes first

Squamous subjects:

  • Gemcitabine 1250 mg/mg(2) administered on Day 1 and Day 8 with Cisplatin 75 mg/m(2) administered on Day 1 of each cycle; or
  • Gemcitabine 1000 mg/mg(2) administered on Day 1 and Day 8 with Carboplatin (AUC 5) administered on Day 1 of each cycle; or
  • Paclitaxel 200 mg/m(2) with Carboplatin (AUC 6) administered on Day 1 of each cycle

Non-Squamous subjects:

  • Pemetrexed 500 mg/m(2) with Cisplatin 75 mg/m(2) administered on Day 1 of each cycle
  • Pemetrexed 500 mg/m(2) Carboplatin (AUC 6) administered on Day 1 of each cycle

Optional crossover:

  • Nivolumab solution for Injection 3 mg/kg Intravenous every 2 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent or study closure
 Biological: Nivolumab
Other Names:
  • BMS-936558
  • MDX-1106
Drug: Gemcitabine
Other Names:
  • Gemzar
Drug: Cisplatin
Other Names:
  • Platinol
Drug: Carboplatin
Other Names:
  • Paraplatin
Drug: Paclitaxel
Other Names:
  • Taxol
Drug: Pemetrexed
Other Names:
  • Alimta
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Progression Free Survival (PFS) as assessed by independent radiology review committee (IRRC) in subjects with strongly Programmed death-ligand 1+ (PD-L1+) tumor expression
[ Time Frame: Up to approximately 33 months ]

PFS is defined as the time from randomization to the date of the first documented tumor progression as determined by the IRRC (per RECIST 1.1), or death due to any cause
Secondary Outcome Measures:
1. Objective response rate (ORR) as determined per IRRC in subjects with strongly PD-L1+ tumor expression
[ Time Frame: Up to approximately 33 months ]

ORR is defined as the number of subjects whose best confirmed objective response is a complete response (CR) or partial response (PR), divided by the number of randomized subjects among strongly PD-L1+ subjects
2. Overall survival (OS) in subjects with strongly PD-L1+ tumor expression
[ Time Frame: At least 33 months ]

OS is defined as the time from randomization to the date of death
3. PFS in all subjects with any PD-L1+ tumor expression
[ Time Frame: Up to approximately 33 months ]
4. Disease related symptom improvement in all subjects
[ Time Frame: Up to approximately 33 months ]

Disease-related symptom improvement rate is defined as the proportion of randomized subjects who had a disease-related symptom improvement as measured by the lung cancer symptom scale (LCSS) among all PD-L1+ subjects
Open or close this module Eligibility
Minimum Age: 18 Years
Maximum Age:
Sex: All
Gender Based:
Accepts Healthy Volunteers: No
Criteria:

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 1
  • Histologically confirmed Stage IV, or Recurrent NSCLC with no prior systemic anticancer therapy
  • Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per response evaluation criteria in solid tumors version (RECIST) 1.1 criteria
  • PD-L1+ on immunohistochemistry testing performed by central lab
  • Men and women, ages ≥ 18 years of age

Exclusion Criteria:

  • Known epidermal growth factor receptor (EGFR) mutations which are sensitive to available targeted inhibitor therapy
  • Known anaplastic lymphoma kinase (ALK) translocations
  • Untreated central nervous system (CNS) metastases
  • Previous malignancies
  • Active, known or suspected autoimmune disease
Open or close this module Contacts/Locations
Central Contact Person: Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:
Email: Clinical.Trials@bms.com
Central Contact Backup: First line of the email MUST contain NCT# and Site #.
Study Officials: Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
Locations: United States, Alabama
Southern Cancer Center
[Recruiting]
Mobile, Alabama, United States, 36608
Contact:Contact: Sherri Arledge, Site 0025 251-607-5281
United States, Arizona
Banner Md Anderson Cancer Center
[Recruiting]
Gilbert, Arizona, United States, 85234
Contact:Contact: Klaus Wagner, Site 0026 480-256-3333
Arizona Oncology Associates
[Recruiting]
Tucson, Arizona, United States, 85704
Contact:Contact: Richard Rosenberg, Site 0034 602-476-5127
United States, California
Stanford Cancer Institute
[Recruiting]
Stanford, California, United States, 94305
Contact:Contact: Heather Wakelee, Site 0016 650-498-6000
United States, Colorado
Anschutz Cancer Pavilion
[Recruiting]
Aurora, Colorado, United States, 80045
Contact:Contact: Ross Camidge, Site 0022 720-848-0290
United States, Connecticut
Yale University
[Recruiting]
New Haven, Connecticut, United States, 06520
Contact:Contact: Scott Gettinger, Site 0020 203-200-1856
United States, Florida
Advanced Medical Specialties
[Recruiting]
Miami, Florida, United States, 33176
Contact:Contact: Paul Kaywin, Site 0030 305-728-1881
Ocala Oncology Center
[Recruiting]
Ocala, Florida, United States, 34471
Contact:Contact: Craig Reynolds, Site 0033 352-732-4938
H. Lee Moffitt Cancer Center
[Recruiting]
Tampa, Florida, United States, 33612
Contact:Contact: Benjamin Creelan, Site 0019 813-745-2010
United States, Georgia
Emory University - Winship Cancer Institute
[Recruiting]
Atlanta, Georgia, United States, 30322
Contact:Contact: Rathi Pillai, Site 0010 404-788-4383
Northwest Georgia Oncology Center, P.C.
[Recruiting]
Marietta, Georgia, United States, 30060
Contact:Contact: Raul Oyola, Site 0013 770-281-5135
United States, Illinois
Local Institution
[Not yet recruiting]
Chicago, Illinois, United States, 60612
Contact:Contact: Site 0037
United States, Kentucky
Baptist Health Lexington
[Recruiting]
Lexington, Kentucky, United States, 40503
Contact:Contact: Firas Badin, Site 0014 859-260-3196
United States, Louisiana
Crescent City Research Consortium, Llc
[Recruiting]
Marrero, Louisiana, United States, 70072
Contact:Contact: Thomas Cosgriff, Site 0035 504-885-8220
United States, Maryland
Local Institution
[Not yet recruiting]
Baltimore, Maryland, United States, 21287
Contact:Contact: Site 0024
United States, Massachusetts
Local Institution
[Not yet recruiting]
Boston, Massachusetts, United States, 02114
Contact:Contact: Site 0036
Local Institution
[Not yet recruiting]
Boston, Massachusetts, United States, 02215
Contact:Contact: Site 0070
United States, New York
Roswell Park Cancer Institute
[Recruiting]
Buffalo, New York, United States, 14263
Contact:Contact: Yujie Zhao, Site 0001 716-845-8387
Laura And Isaac Perlmutter Cancer Center
[Recruiting]
New York, New York, United States, 10016
Contact:Contact: Abraham Chachoua, Site 0009 212-263-2562
Memorial Sloan Kettering Cancer Center
[Recruiting]
New York, New York, United States, 10065
Contact:Contact: Jamie Chaft, Site 0005 646-888-4545
United States, North Carolina
University Of North Carolina At Chapel Hill
[Recruiting]
Chapel Hill, North Carolina, United States, 27599
Contact:Contact: Thomas E Stinchcombe, Site 0021 919-966-7829
Duke University Medical Center
[Recruiting]
Durham, North Carolina, United States, 27710
Contact:Contact: Neal Ready, Site 0003 919-681-4768
United States, Ohio
University Hospitals Of Cleveland
[Recruiting]
Cleveland, Ohio, United States, 44106
Contact:Contact: Neelesh Sharma, Site 0012 216-844-7026
The Ohio State University
[Recruiting]
Columbus, Ohio, United States, 43210
Contact:Contact: Bo Chao, Site 0027 614-293-9424
United States, Oregon
Oregon Health & Science University
[Recruiting]
Portland, Oregon, United States, 97239
Contact:Contact: Jeremy Cetnar, Site 0017 503-494-5601
United States, Pennsylvania
Network Office Of Research And Innovation
[Recruiting]
Allentown, Pennsylvania, United States, 18103
Contact:Contact: Suresh Nair, Site 0007 610-402-9543
Local Institution
[Not yet recruiting]
Philadelphia, Pennsylvania, United States, 19104
Contact:Contact: Site 0054
Fox Chase Cancer Center
[Recruiting]
Philadelphia, Pennsylvania, United States, 19111
Contact:Contact: Hossein Borghaei, Site 0002 513-751-2273
Upmc Cancer Pavilion
[Recruiting]
Pittsburgh, Pennsylvania, United States, 15232
Contact:Contact: Liza Villaruz, Site 0018 412-235-1316
United States, South Carolina
Hollings Cancer Center
[Recruiting]
Charleston, South Carolina, United States, 29425
Contact:Contact: Keisuke Shirai, Site 0011 843-792-6429
St Francis Hospital
[Recruiting]
Greenville, South Carolina, United States, 29601
Contact:Contact: Fahd Quddus, Site 0038 864-255-1517
United States, Tennessee
Vanderbilt-Ingram Cancer Ctr
[Recruiting]
Nashville, Tennessee, United States, 37232
Contact:Contact: Leora Horn, Site 0008 615-936-5806
United States, Texas
University Of Texas Southwestern Medical Center
[Recruiting]
Dallas, Texas, United States, 75390
Contact:Contact: David E Gerber, Site 0006 214-648-1688
The University Of Texas Md Anderson Cancer Center
[Recruiting]
Houston, Texas, United States, 77030
Contact:Contact: George Blumenschein, Site 0023 713-792-6966
Cancer Care Centers Of South Texas
[Recruiting]
San Antonio, Texas, United States, 78212
Contact:Contact: Joseph Mccracken, Site 0032 210-224-6431
United States, Washington
Yakima Valley Memorial Hospital/North Star Lodge
[Recruiting]
Yakima, Washington, United States, 98902
Contact:Contact: Thomas Boyd, Site 0029 509-574-3493
Argentina
Local Institution
[Recruiting]
Cordoba, Argentina, 5000
Contact:Contact: Site 0048
Local Institution
[Recruiting]
Cordoba, Argentina, 5000
Contact:Contact: Site 0050
Argentina, Buenos Aires
Local Institution
[Recruiting]
Berazategui, Buenos Aires, Argentina, 1880
Contact:Contact: Site 0051
Local Institution
[Recruiting]
Capital Federal, Buenos Aires, Argentina, 1426
Contact:Contact: Site 0049
Local Institution
[Not yet recruiting]
Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina, 1181
Contact:Contact: Site 0052
Australia, New South Wales
Local Institution
[Not yet recruiting]
Camperdown, New South Wales, Australia, 2050
Contact:Contact: Site 0090
Australia, Queensland
Local Institution
[Recruiting]
Brisbane, Queensland, Australia, 4102
Contact:Contact: Site 0091
Australia, South Australia
Local Institution
[Recruiting]
Elizabeth Vale, South Australia, Australia, 5112
Contact:Contact: Site 0071
Australia, Victoria
Local Institution
[Recruiting]
Fitzroy, Victoria, Australia, 3065
Contact:Contact: Site 0072
Local Institution
[Recruiting]
Heidelberg, Victoria, Australia, 3084
Contact:Contact: Site 0104
Austria
Local Institution
[Recruiting]
Wels, Austria, 4600
Contact:Contact: Site 0088
Local Institution
[Recruiting]
Wien, Austria, 1090
Contact:Contact: Site 0087
Belgium
Local Institution
[Recruiting]
Brussels, Belgium, 1090
Contact:Contact: Site 0044
Local Institution
[Recruiting]
Edegem, Belgium, 2650
Contact:Contact: Site 0055
Local Institution
[Recruiting]
Gent, Belgium, B-9000
Contact:Contact: Site 0056
Local Institution
[Not yet recruiting]
Leuven, Belgium, 3000
Contact:Contact: Site 0062
Brazil
Local Institution
[Not yet recruiting]
Sao Paulo, Brazil, 01308
Contact:Contact: Site 0136
Local Institution
[Not yet recruiting]
Sao Paulo, Brazil, 01509
Contact:Contact: Site 0137
Brazil, Rio Grande Do Sul
Local Institution
[Not yet recruiting]
Ijui, Rio Grande Do Sul, Brazil, 98700
Contact:Contact: Site 0134
Local Institution
[Not yet recruiting]
Porto Alegre, Rio Grande Do Sul, Brazil, 90610
Contact:Contact: Site 0133
Brazil, Sao Paulo
Local Institution
[Not yet recruiting]
Barretos, Sao Paulo, Brazil, 14780
Contact:Contact: Site 0135
Canada, Alberta
Tom Baker Cancer Centre
[Recruiting]
Calgary, Alberta, Canada, T2N 4N2
Contact:Contact: Don G Morris, Site 0086 403-521-3451
Canada, Ontario
Juravinski Cancer Centre
[Recruiting]
Hamilton, Ontario, Canada, L8V 5C2
Contact:Contact: Rosalyn Juergens, Site 0115 905-387-9711 Ext. x64604
Princess Margaret Cancer Centre
[Recruiting]
Toronto, Ontario, Canada, M5G 2M9
Contact:Contact: Natasha Leighl, Site 0113 416-946-4501 Ext. 7890
Canada, Quebec
Chum-Hopital Notre-Dame
[Recruiting]
Montreal, Quebec, Canada, H2L 4M1
Contact:Contact: Normand Blais, Site 0110 514-890-8000 Ext. x24634
Centre De Sante Et De Services Sociaux Rimouski Neigette
[Recruiting]
Rimouski, Quebec, Canada, G5L 5T1
Contact:Contact: Marie-Claude Foley, Site 0109 418-724-3000 Ext. 8029
Czech Republic
Local Institution
[Recruiting]
Olomouc, Czech Republic, 775 20
Contact:Contact: Site 0059
Local Institution
[Recruiting]
Ostrava - Poruba, Czech Republic, 708 52
Contact:Contact: Site 0061
Local Institution
[Recruiting]
Praha 8, Czech Republic, 180 81
Contact:Contact: Site 0058
Local Institution
[Recruiting]
Usti nad Labem, Czech Republic, 401 13
Contact:Contact: Site 0060
Finland
Local Institution
[Recruiting]
Helsinki, Finland, 00029
Contact:Contact: Site 0120
Local Institution
[Recruiting]
Tampere, Finland, 33521
Contact:Contact: Site 0119
Local Institution
[Recruiting]
Vaasa, Finland, 65130
Contact:Contact: Site 0118
France
Local Institution
[Recruiting]
Caen, France, 14000
Contact:Contact: Site 0123
Local Institution
[Not yet recruiting]
Lille, France, 59000
Contact:Contact: Site 0105
Local Institution
[Recruiting]
Marseille Cedex 20, France, 13915
Contact:Contact: Site 0102
Local Institution
[Not yet recruiting]
Pontoise Cedex, France, 95303
Contact:Contact: Site 0167
Local Institution
[Recruiting]
Rennes Cedex 9, France, 35033
Contact:Contact: Site 0100
Local Institution
[Not yet recruiting]
Strasbourg, France, 67090
Contact:Contact: Site 0140
Germany
Local Institution
[Recruiting]
Bamberg, Germany, 96049
Contact:Contact: Site 0074
Local Institution
[Recruiting]
Gerlingen, Germany, 70839
Contact:Contact: Site 0066
Local Institution
[Recruiting]
Grosshansdorf, Germany, 22927
Contact:Contact: Site 0065
Local Institution
[Recruiting]
Heidelberg, Germany, 69126
Contact:Contact: Site 0064
Local Institution
[Recruiting]
Koeln, Germany, 50937
Contact:Contact: Site 0063
Local Institution
[Recruiting]
Wiesbaden, Germany, 65199
Contact:Contact: Site 0092
Greece
Local Institution
[Recruiting]
Athens, Greece, 11527
Contact:Contact: Site 0075
Greece, Creta
Local Institution
[Recruiting]
Heraklion, Creta, Greece, 71110
Contact:Contact: Site 0073
Hungary
Local Institution
[Recruiting]
Budapest, Hungary, 1121
Contact:Contact: Site 0126
Local Institution
[Recruiting]
Debrecen, Hungary, 4032
Contact:Contact: Site 0116
Local Institution
[Recruiting]
Matrahaza, Hungary, 3233
Contact:Contact: Site 0094
Italy
Local Institution
[Not yet recruiting]
Avellino, Italy, 83024
Contact:Contact: Site 0084
Local Institution
[Recruiting]
Livorno, Italy, 57100
Contact:Contact: Site 0079
Local Institution
[Recruiting]
Milano, Italy, 20141
Contact:Contact: Site 0143
Local Institution
[Recruiting]
Napoli, Italy, 80131
Contact:Contact: Site 0142
Local Institution
[Recruiting]
Perugia, Italy, 06132
Contact:Contact: Site 0083
Local Institution
[Recruiting]
Terni, Italy, 05100
Contact:Contact: Site 0082
Mexico, Distrito Federal
Local Institution
[Not yet recruiting]
Mexico City, Distrito Federal, Mexico, 14080
Contact:Contact: Site 0117
Mexico, Jalisco
Local Institution
[Recruiting]
Guadalajara, Jalisco, Mexico, 44280
Contact:Contact: Site 0122
Mexico, Yucatan
Local Institution
[Not yet recruiting]
Merida, Yucatan, Mexico, 97000
Contact:Contact: Site 0124
Netherlands
Local Institution
[Recruiting]
Amsterdam, Netherlands, 1066 CX
Contact:Contact: Site 0045
Local Institution
[Recruiting]
Groningen, Netherlands, 9713 GZ
Contact:Contact: Site 0057
Local Institution
[Recruiting]
Rotterdam, Netherlands, 3015 CE
Contact:Contact: Site 0046
Poland
Local Institution
[Not yet recruiting]
Bydgoszcz, Poland, 85-796
Contact:Contact: Site 0114
Local Institution
[Recruiting]
Krakow, Poland, 31-202
Contact:Contact: Site 0131
Local Institution
[Recruiting]
Lodz, Poland, 93-513
Contact:Contact: Site 0139
Local Institution
[Recruiting]
Warszawa, Poland, 02-781
Contact:Contact: Site 0089
Local Institution
[Recruiting]
Wodzislaw Slaski, Poland, 44-300
Contact:Contact: Site 0093
Romania
Local Institution
[Recruiting]
Cluj Napoca, Romania, 400015
Contact:Contact: Site 0068
Local Institution
[Recruiting]
Cluj-napoca, Romania, 400352
Contact:Contact: Site 0067
Local Institution
[Recruiting]
Ploiesti, Romania, 100337
Contact:Contact: Site 0069
Spain
Local Institution
[Recruiting]
Barcelona, Spain, 08035
Contact:Contact: Site 0040
Local Institution
[Recruiting]
Las Palmas De Gran Canaria, Spain, 35016
Contact:Contact: Site 0041
Local Institution
[Recruiting]
Madrid, Spain, 28050
Contact:Contact: Site 0047
Local Institution
[Recruiting]
Malaga, Spain, 29010
Contact:Contact: Site 0042
Local Institution
[Recruiting]
Sevilla, Spain, 41013
Contact:Contact: Site 0039
Local Institution
[Recruiting]
Valencia, Spain, 46014
Contact:Contact: Site 0043
Sweden
Local Institution
[Recruiting]
Stockholm, Sweden, 171 76
Contact:Contact: Site 0127
Local Institution
[Recruiting]
Uppsala, Sweden, 751 85
Contact:Contact: Site 0125
Switzerland
Local Institution
[Recruiting]
Chur, Switzerland, 7000
Contact:Contact: Site 0076
Local Institution
[Recruiting]
Lausanne, Switzerland, 1011
Contact:Contact: Site 0077
Local Institution
[Recruiting]
Zuerich, Switzerland, 8091
Contact:Contact: Site 0078
Turkey
Local Institution
[Not yet recruiting]
Adana, Turkey, 01120
Contact:Contact: Site 0128
Local Institution
[Not yet recruiting]
Ankara, Turkey, 06500
Contact:Contact: Site 0129
Local Institution
[Not yet recruiting]
Kayseri, Turkey, 38039
Contact:Contact: Site 0130
United Kingdom, Greater London
Local Institution
[Recruiting]
London, Greater London, United Kingdom, N18 1QX
Contact:Contact: Site 0098
United Kingdom, Greater Manchester
Local Institution
[Recruiting]
Manchester, Greater Manchester, United Kingdom, M20 4XB
Contact:Contact: Site 0097
United Kingdom, Yorkshire
Local Institution
[Recruiting]
Leeds, Yorkshire, United Kingdom, LS9 7TF
Contact:Contact: Site 0053
Open or close this module IPDSharing
Plan to Share IPD:
Open or close this module References
Links: Description: BMS clinical trial educational resource
Available IPD/Information:
Scroll up to access the controls Scroll to the Study top
U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services